[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregestational-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregestational-diabetes":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610231","phase-4-once-daily-vs-twice-daily-insulin-glargine-in-pregestational-diabetes-management-100610231",false,"NCT07224893","Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","Once-Daily Versus Twice-Daily Insulin Glargine in the Management of Patients With Pregestational Diabetes Requiring Insulin","Inclusion Criteria:\n\n* Patients older than 18 years of age;\n* The patient is fluent in English, physically and mentally able to understand the informed consent, and is willing to participate in this study;\n* Type II diabetes mellitus requiring insulin;\n* The patient is between 24 weeks 0 days and 28 weeks 0 days of gestation at the time of enrollment. Gestational age will be determined by last menstrual period, confirmed with a first trimester ultrasound, per the recommended guidelines by the American College of Obstetricians and Gynecologists.\n* Currently using or willing to use a clinically indicated continuous glucose monitor for glycemic management\n\nExclusion Criteria:\n\n* Known allergy or reaction to insulin glargine, or concurrent medical condition where the use of insulin glargine is contraindicated;\n* Contraindication to CGM use, patient declines CGM use, or CGM not covered by patient's insurance;\n* Known or suspected fetal anomaly or aneuploidy;\n* Prisoners;\n* Ongoing prenatal care outside EVMS or planned delivery outside Sentara Norfolk General Hospital.","FEMALE","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a group that takes it twice. Continuous glucose monitoring will be used to track blood sugar levels. The main question the study aims to answer is: Will using insulin glargine twice a day instead of once lead to a better glucose time in range?",[26,27],"Pregestational Diabetes","Pregnancy",[29],"continuous glucose monitoring","RECRUITING","2026-05-13",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":20},"2026-05-18",{"date":38,"type":20},"2027-12-01",{"name":40,"class":41},"Eastern Virginia Medical School","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100613624","cgm-accuracy-in-pregnancy-study-100613624","NCT07269015","CGM Accuracy in Pregnancy Study","Evaluation of the Accuracy of Continuous Glucose Monitoring Systems and Educational Needs in Pregnant Women With Diabetes: A Comparison Between Dexcom One Plus and FreeStyle Libre 2 Plus","Inclusion Criteria:\n\n* Pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes, diagnosed before 32 weeks of gestation\n* Age ≥18 years\n* Willingness to wear two CGM systems simultaneously\n* Possession of a smartphone compatible with LibreLink\n* Ability to sign informed consent\n\nExclusion Criteria:\n\n* Comorbidities affecting glucose metabolism\n* Inability to use CGM devices or perform capillary glucose testing",{"count":51,"type":20},66,[53],"NA","Pregnancy in women with diabetes remains a high-risk condition, requiring strict glycemic control due to rapid physiological changes that affect insulin sensitivity. Continuous glucose monitoring (CGM) provides detailed glucose trends, but the accuracy of newer, affordable systems such as Dexcom One Plus and FreeStyle Libre 2 Plus has not been evaluated during pregnancy.\n\nThis prospective interventional study aims to compare the accuracy of these two CGM systems-both worn simultaneously-using capillary glucose as the reference. The study also evaluates educational needs, skills, attitudes, digital competence, lifestyle habits, and patient-reported outcomes among pregnant women with type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes (GDM).",[26,56],"Continuous Glucose Monitoring",[58,29,59],"type 2 diabetes","pregnancy","NOT_YET_RECRUITING","2025-12-04",{"date":63,"type":34},"2025-12-08",{"date":65,"type":20},"2025-12",{"date":67,"type":20},"2027-01",{"name":69,"class":41},"Hospital Mutua de Terrassa",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100612216","glucose-control-in-type-2-diabetes-in-pregnancy-100612216","NCT07250698","Glucose Control in Type 2 Diabetes in Pregnancy","Postprandial Walks for Glucose Control in Type 2 Diabetes in Pregnancy","Inclusion Criteria:\n\n* Singleton gestation\n* Known diagnosis of Type 2 diabetes OR meets new diagnosis of Type 2 diabetes in the first trimester (up to 13 weeks and 6 days)\n* Age ≥18 and \\\u003C50 years\n* Gestational age \\\u003C32 weeks 0 days gestation\n\nExclusion Criteria:\n\n* Non-English as the primary language\n* Inability to participate in 20 minutes of walking at a time\n* Known or suspected fetal anomaly or aneuploidy\n* Prisoners\n* Management of diabetes outside of study location","50 Years",{"count":79,"type":20},40,[53],"The goal of this clinical trial is to evaluate the effect of physical activity on glucose control in pregnant patients with pregestational Type 2 diabetes. The main question it seeks to answer is \"will physical activity following a meal improve blood sugar control in pregnant women with Type 2 diabetes?\" Researchers will compare the glucose control of two groups: one that walks for 20 minutes after each meal, and one that does not.",[26,83],"Type 2 Diabetes",[85,29],"exercise","2025-11-18",{"date":88,"type":34},"2025-11-26",{"date":65,"type":20},{"date":91,"type":20},"2026-12",{"name":40,"class":41}]